
    
      This 2-group, double-blind, placebo-controlled, 14-week study (N=100) will investigate the
      efficacy of cognitive behavioral therapy plus lisdexamfetamine vs. placebo to treat cocaine
      dependence. We hypothesize that lisdexamfetamine will reduce cocaine use (primary outcome),
      as well as cocaine craving and impulsivity (secondary outcomes) vs. placebo.
    
  